Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX002100 in Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07863609Phase 1Not yet recruiting
- Sponsor
- Tectonic Therapeutic
- Start
- Dec 2026
- Primary completion
- Apr 2028
01
Overview
Phase 1, open-label, single-arm trial of TX2100 in hereditary hemorrhagic telangiectasia (HHT), sponsored by Tectonic Therapeutic. Primary endpoints: Incidence of adverse events (AEs), including serious adverse events (SAEs) at Day 225 and Incidence of clinically significant changes from baseline in safety laboratory assessments at Day 225. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
TX2100
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT07863609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863609.